약물에 의한 중증 피부반응 = Severe Cutaneous Adverse Reaction

다국어 초록 (Multilingual Abstract)

Severe adverse cutaneous reactions (SCARs) include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Although recent advances in pharmacogenomics have revealed the association between specific human leukocyte antigens (HLAs) and certain drug-induced SCARs, such associations were found in a limited number of drug-associated SCARs and are not sufficient to explain many other drug-related SCARs. After introducing research on the HLA-restricted T cell response, the role of the T cell receptor in drug binding was emphasized and a new concept called “pharmacological interactions of drug with immune receptors” has been conceptualized over recent decades. Currently, many international and domestic collaborative consortia have been formed and should enable the phenotypic standardization of SCARs at the earliest practicable time to provide valuable insights into its pathogenesis and to find an ideal method to prevent patients from developing SCARs. (Korean J Med 2014,87:665-674)

참고문헌 (Reference)

1 Kardaun SH, "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist" 156 : 609-611, 2007

2 Ishida T, "The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome" 69 : 798-805, 2014

3 Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management" 33 : 10-16, 2014

4 Harr T, "Stevens-Johnson syndrome and toxic epidermal necrolysis" 97 : 149-166, 2012

5 Park WB, "Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir" 48 : 365-367, 2009

6 Lebargy F, "Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study" 23 : 1237-1244, 1997

7 Kang HR, "Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans" 21 : 303-307, 2011

8 Chung WH, "Medical genetics: a marker for Stevens-Johnson syndrome" 428 : 486-, 2004

9 Jung JW, "HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency" 26 : 3567-3572, 2011

10 Hung SI, "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol" 102 : 4134-4139, 2005

11 Mallal S, "HLA-B*5701 screening for hypersensitivity to abacavir" 358 : 568-579, 2008

12 McCormack M, "HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans" 364 : 1134-1143, 2011

13 Yip VL, "HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review" 92 : 757-765, 2012

14 Hung SI, "Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions" 16 : 297-306, 2006

15 Chang YS, "Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management" 26 : 123-129, 2007

16 Yager JA, "Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review" 25 : 406-e464, 2014

17 Camous X, "Drug reaction with eosinophilia and systemic symptoms: an update on pathogenesis" 24 : 730-735, 2012

18 Phillips EJ, "Drug hypersensitivity: pharmacogenetics and clinical syndromes" 127 (127): S60-66, 2011

19 Pichler WJ, "Drug hypersensitivity reactions: pathomechanism and clinical symptoms" 94 : 645-664, 2010

20 Husain Z, "DRESS syndrome: part I. Clinical perspectives" 68 : 693.e1-693.e14, 2013

21 Husain Z, "DRESS syndrome: Part II. Management and therapeutics" 68 : 709.e1-709.e9, 2013

22 김동현, "Comparison of Diagnostic Criteria and Determination of Prognostic Factors for Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome" 대한천식알레르기학회 6 (6): 216-221, 2014

23 Yang MS, "Clinical features and prognostic factors in severe cutaneous drug reactions" 162 : 346-354, 2013

24 Bastuji-Garin S, "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme" 129 : 92-96, 1993

25 Chen P, "Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan" 364 : 1126-1133, 2011

26 Kim SH, "Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans" 97 : 190-197, 2011

27 Tohkin M, "A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients" 13 : 60-69, 2013

28 Weinand C, "27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents" 39 : 1449-1455, 2013